A
Adam Castano
Researcher at Columbia University Medical Center
Publications - 36
Citations - 3563
Adam Castano is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Cardiac amyloidosis & Transthyretin. The author has an hindex of 17, co-authored 35 publications receiving 2527 citations. Previous affiliations of Adam Castano include Columbia University.
Papers
More filters
Journal ArticleDOI
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Julian D. Gillmore,Mathew S. Maurer,Rodney H. Falk,Giampaolo Merlini,Thibaud Damy,Angela Dispenzieri,Ashutosh D. Wechalekar,John L. Berk,John L. Berk,Candida Cristina Quarta,Martha Grogan,Helen J. Lachmann,Sabahat Bokhari,Adam Castano,Sharmila Dorbala,Geoff B. Johnson,Andor W. J. M. Glaudemans,Tamer Rezk,Marianna Fontana,Giovanni Palladini,Paolo Milani,P.L Guidalotti,Katarina Flatman,Thirusha Lane,Frederick W. Vonberg,Carol J. Whelan,James C. Moon,Frederick L. Ruberg,Frederick L. Ruberg,Edward J. Miller,David F. Hutt,Bouke P. C. Hazenberg,Claudio Rapezzi,Philip N. Hawkins +33 more
TL;DR: Bone scintigraphy enables the diagnosis of cardiac ATTR amyloidosis to be made reliably without the need for histology in patients who do not have a monoclonal gammopathy, and proposes noninvasive diagnostic criteria that are applicable to the majority of patients with this disease.
Journal ArticleDOI
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.
TL;DR: In this paper, the discriminatory ability of 99mTc-pyrophosphate scintigraphy in immunoglobulin light chain (AL) versus transthyretin-related cardiac amyloidoses (ATTR) was validated.
Journal ArticleDOI
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Adam Castano,David L. Narotsky,Nadira Hamid,Omar K. Khalique,Rachelle Morgenstern,Albert DeLuca,Jonah Rubin,Codruta Chiuzan,Tamim Nazif,Torsten Vahl,Isaac George,Susheel Kodali,Martin B. Leon,Rebecca T. Hahn,Sabahat Bokhari,Mathew S. Maurer +15 more
TL;DR: Transthyretin cardiac amyloidosis is prevalent in 16% of patients with severe calcific AS undergoing TAVR and is associated with a severe AS phenotype of low-flow low-gradient with mildly reduced ejection fraction.
Journal ArticleDOI
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
Adam Castano,Muhammad Haq,David L. Narotsky,Jeff Goldsmith,Richard Weinberg,Rachelle Morgenstern,Ted Pozniakoff,Frederick L. Ruberg,Edward J. Miller,John L. Berk,Angela Dispenzieri,Martha Grogan,Geoffrey B. Johnson,Sabahat Bokhari,Mathew S. Maurer +14 more
TL;DR: Tc 99m PYP cardiac imaging conferred a high level of sensitivity and specificity for differentiation of patients with ATTR cardiac amyloidosis (irrespective of genotype) from patients with AL cardiac ameloidosis and patients with nonamyloid heart failure with preserved ejection fraction.
Journal ArticleDOI
Transthyretin Cardiac Amyloidosis in Older Americans.
TL;DR: The epidemiology, pathophysiology, and clinical manifestations, as well as diagnostic strategies and treatment, of ATTR in older adults are covered, including nuclear scintigraphy agents using 99mTc-phosphate derivatives combined with assessment for monoclonal proteins are eliminating the need for tissue confirmation in ATTR.